PlumX Metrics
Embed PlumX Metrics

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

British Journal of Cancer, ISSN: 0007-0920, Vol: 88, Issue: 12, Page: 1851-1858
2003
  • 78
    Citations
  • 0
    Usage
  • 17
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    78
    • Citation Indexes
      71
    • Policy Citations
      5
      • Policy Citation
        5
    • Clinical Citations
      2
      • PubMed Guidelines
        2
  • Captures
    17

Article Description

A multicentre study evaluated the efficacy and safety of darbepoetin alpha administered weekly (QW), every 3 weeks (Q3W), and every 4 weeks (Q4W) to anaemic patients with cancer not concurrently receiving chemotherapy or radiotherapy. The QW portion (n = 102) was an open-label, sequential, dose-escalation design; cohorts received darbepoetin alpha QW by subcutaneous (s.c.) injection at 0.5, 1.0, 2.25, or 4.5 μg kg week for 12 weeks. The 12-week placebo-controlled, double- blind Q3W (6.75 μg kg) and Q4W (6.75 or 10.0 μg kg) schedules (n = 86), which enrolled different patients, took place after the QW schedule and were followed by a 12-week, open-label phase. Patients were evaluated for change in haemoglobin end points and red blood cell transfusions, serum darbepoetin alpha concentration, and safety. Selected domains of health-related quality of life (HRQOL) were measured. With QW dosing, at least 70% of each cohort had a haemoglobin increase from baseline of > 2 gdl or a concentration > 12g dl (haematopoietic response). In the 4.5 μg kg QW cohort, all patients achieved a haematopoietic response (100%; 95% confidence interval (Cl)= 100, 100). In the Q3W and Q4W schedules, all cohorts had at least 60% of patients who achieved a haematopoietic response. Darbepoetin alpha effectively increases haemoglobin concentration when given QW, Q3W, or Q4W. Less-frequent administration may benefit patients with chronic anaemia of cancer and their caregivers alike. © 2003 Cancer Research UK.

Bibliographic Details

R. E. Smith; N. S. Tchekmedyian; D. Chan; L. A. Meza; D. W. Northfelt; R. Patel; M. Austin; A. B. Colowick; G. Rossi; J. Glaspy

Springer Science and Business Media LLC

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know